23:48 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Liver disease Mouse studies suggest inhibiting IKKα or its activator MAP3K14 could help treat liver disease. In a partial hepatectomy mouse model of liver injury, hepatocyte-specific knockout of MAP3K14 or IKKα increased hepatocyte proliferation...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Company News

J&J, Tracon deal

Johnson & Johnson’s Janssen Pharmaceutica N.V. unit granted Tracon exclusive, worldwide development rights to TRC253 (formerly JNJ-63576253 ) and TRC694 (formerly JNJ-64290694 ). The pharma’s J&J Innovation-JJDC venture arm made a $5 million equity investment...
07:00 , May 7, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MAP kinase kinase kinase 14 (MAP3K14; NIK); tumor necrosis factor (TNF) receptor-associated factor 3 (TRAF3)

Cancer INDICATION: B cell lymphoma In vitro, mouse and patient sample studies suggest inhibiting MAP3K14 could help treat diffuse large B cell lymphoma (DLBCL). Of 119 DLBCL patient samples, 15% had inactivating mutations in TRAF3...
08:00 , Feb 6, 2014 |  BC Innovations  |  Cover Story

Germinating MALT1

AstraZeneca plc has teamed up with the Flanders Institute for Biotechnology and the Centre for Drug Design and Discovery to make the first disclosed industry play for inhibitors of MALT1 . The deal announcement caps...
07:00 , Jun 7, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes MAP kinase kinase kinase 14 (MAP3K14; NIK) Mouse studies suggest inhibiting NIK in the liver could help treat type...
08:00 , Feb 17, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Lymphoma MAP kinase kinase kinase 14 (MAP3K14; NIK); baculoviral IAP repeat-containing 3 (BIRC3; cIAP2); mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1) A...
07:00 , Jun 7, 2010 |  BC Week In Review  |  Company News

Nichi-Iko, sanofi-aventis deal

The companies will form the JV sanofi-aventis Nichi-Iko K.K., to market generics in Japan. sanofi-aventis will own 51% and Nichi-Iko will own 49%. sanofi-aventis also will purchase 1.5 million shares of Nichi-Iko at an undisclosed...
07:00 , May 14, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammatory disease Mitogen-activated protein kinase kinase kinase 14 (MAP3K14; NIK) Studies in mice suggest that inhibiting MAP3K14 could help treat inflammatory...
08:00 , Jan 5, 2004 |  BC Week In Review  |  Company News

Predix management update

Predix Pharmaceuticals Inc. , Woburn, Mass.   Business: Computational chemistry/biology   Hired: Chen Schor as CBO, formerly a partner and CFO at Yozma Venture Capital Group; he replaces Nik Hayes, who departed  ...
07:00 , Aug 18, 2003 |  BC Week In Review  |  Company News

Predix management update

Predix Pharmaceuticals Inc. , Woburn, Mass.   Business: Computational chemistry/biology   Transition: CEO Michael Kauffman to CEO of the company newly formed by the merger of Predix with Physiome Sciences Inc. ; and Physiome CFO...